Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...

Glucose Market Technological advancements and rising awareness in diabetes management are driving growth in the glucose market, enhancing a ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...